August 29th 2025
Teva announced approval of the generic formulation of Saxenda, which could help expand access to the extremely popular class of antiobesity medications.
Concurrent Management of Achalasia and Morbid Obesity
The development of a standardized treatment that simultaneously addresses achalasia and obesity is becoming more imperative as obesity becomes epidemic in the US. Here’s a case in point.